Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease

NCT02133924 is registered in ClinicalTrials.gov with John Levine as lead sponsor.

NCT NCT02133924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02133924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Lead sponsor
John Levine
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2016
Completion date
November 21, 2021
Enrollment
76 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

acute graft versus host disease